Human CellExp Osteoprotegerin / TNFRSF11B, human recombinant protein
TNFRSF11B, OCIF, OPG, Osteoprotegerin
|Calculated MW||This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 44.4 kDa. The predicted N-terminus is Glu 22. DTT-reduced Protein migrates as 55 kDa due to glycosylation.|
|Other Names||TNFRSF11B, OCIF, OPG, Osteoprotegerin|
|Target/Specificity||Osteoprotegerin / TNFRSF11B|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in PBS, pH 7.4. Do not vortex.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) is also known as Osteoclastogenesis inhibitory factor (OCIF), Osteoprotegerin (OPG). TNFRSF11B is a secreted homodimer protein, which can interact with TNFSF10 and TNFSF11. TNFRSF11B acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TNFRSF11B inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Simonet W.S.,et al.Cell 89:309-319(1997).
Yasuda H.,et al.Endocrinology 139:1329-1337(1998).
Morinaga T.,et al.Eur. J. Biochem. 254:685-691(1998).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Suzuki Y.,et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.